PMID- 37657201
OWN - NLM
STAT- Publisher
LR  - 20231001
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 328
DP  - 2023 Oct
TI  - Recreational cannabis use over time in individuals at clinical high risk for 
      psychosis: Lack of associations with symptom, neurocognitive, functioning, and 
      treatment patterns.
PG  - 115420
LID - S0165-1781(23)00370-0 [pii]
LID - 10.1016/j.psychres.2023.115420 [doi]
AB  - Recreational cannabis use has recently gained considerable interest as an 
      environmental risk factor that triggers the onset of psychosis. To date, however, 
      the evidence that cannabis is associated with negative outcomes in individuals at 
      clinical high risk (CHR) for psychosis is inconsistent. The present study tracked 
      cannabis usage over a 2-year period and examined its associations with clinical 
      and neurocognitive outcomes, along with medication rates. CHR youth who 
      continuously used cannabis had higher neurocognition and social functioning over 
      time, and decreased medication usage, relative to non-users. Surprisingly, 
      clinical symptoms improved over time despite the medication decreases.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Carrion, Ricardo E
AU  - Carrion RE
AD  - Division of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, 
      75-59 263rd Street, Glen Oaks, NY 11004, United States; Institute of Behavioral 
      Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, 
      NY, United States; Department of Psychiatry, Donald and Barbara Zucker School of 
      Medicine at Hofstra/Northwell, Hempstead, New York 11549, United States.
FAU - Auther, Andrea M
AU  - Auther AM
AD  - Division of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, 
      75-59 263rd Street, Glen Oaks, NY 11004, United States; Department of Psychiatry, 
      Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New 
      York 11549, United States.
FAU - McLaughlin, Danielle
AU  - McLaughlin D
AD  - Division of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, 
      75-59 263rd Street, Glen Oaks, NY 11004, United States.
FAU - Adelsheim, Steven
AU  - Adelsheim S
AD  - Department of Psychiatry, Stanford University School of Medicine, Palo Alto, 
      California, United States.
FAU - Burton, Cynthia Z
AU  - Burton CZ
AD  - Department of Psychiatry & Behavioral Health, The Ohio State University, 
      Columbus, Ohio, United States.
FAU - Carter, Cameron S
AU  - Carter CS
AD  - Department of Psychiatry and Behavioral Sciences, Imaging Research Center, the 
      University of California at Davis, Sacramento, CA, United States; Department of 
      Psychology, Center for Neuroscience, the University of California at Davis, 
      Davis, CA, United States.
FAU - Niendam, Tara
AU  - Niendam T
AD  - Department of Psychiatry and Behavioral Sciences, Imaging Research Center, the 
      University of California at Davis, Sacramento, CA, United States; Department of 
      Psychology, Center for Neuroscience, the University of California at Davis, 
      Davis, CA, United States.
FAU - Ragland, J Daniel
AU  - Ragland JD
AD  - Department of Psychiatry and Behavioral Sciences, Imaging Research Center, the 
      University of California at Davis, Sacramento, CA, United States.
FAU - Sale, Tamara G
AU  - Sale TG
AD  - EASA Center for Excellence at Oregon Health & Science University, PSU School of 
      Public Health, Portland, Oregon, United States.
FAU - Taylor, Stephan F
AU  - Taylor SF
AD  - Department of Psychiatry & Behavioral Health, The Ohio State University, 
      Columbus, Ohio, United States.
FAU - Tso, Ivy F
AU  - Tso IF
AD  - Department of Psychiatry & Behavioral Health, The Ohio State University, 
      Columbus, Ohio, United States.
FAU - McFarlane, William R
AU  - McFarlane WR
AD  - Tufts University School of Medicine, Boston, MA, United States; Maine Medical 
      Center Research Institute, Portland, ME, United States.
FAU - Cornblatt, Barbara A
AU  - Cornblatt BA
AD  - Division of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, 
      75-59 263rd Street, Glen Oaks, NY 11004, United States; Institute of Behavioral 
      Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, 
      NY, United States; Department of Psychiatry, Donald and Barbara Zucker School of 
      Medicine at Hofstra/Northwell, Hempstead, New York 11549, United States; 
      Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, New York 11549, United States. Electronic address: 
      bcornblatt@northwell.edu.
LA  - eng
PT  - Journal Article
DEP - 20230815
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
SB  - IM
OTO - NOTNLM
OT  - Cannabis
OT  - Clinical high risk for psychosis
OT  - Prevention
COIS- Declaration of Competing Interest There are no conflicts of interest for any of 
      the authors with respect to the data in this paper or for the study. Dr. Niendam 
      is co-founder and shareholder in Safari Health Inc. Dr. Cornblatt was the 
      original developer of the CPT-IP. Dr. McFarlane provides training on request to 
      public and not-for-profit clinical services implementing psychosis early 
      intervention programs.
EDAT- 2023/09/02 05:42
MHDA- 2023/09/02 05:42
CRDT- 2023/09/01 18:04
PHST- 2023/03/29 00:00 [received]
PHST- 2023/07/17 00:00 [revised]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/09/02 05:42 [pubmed]
PHST- 2023/09/02 05:42 [medline]
PHST- 2023/09/01 18:04 [entrez]
AID - S0165-1781(23)00370-0 [pii]
AID - 10.1016/j.psychres.2023.115420 [doi]
PST - ppublish
SO  - Psychiatry Res. 2023 Oct;328:115420. doi: 10.1016/j.psychres.2023.115420. Epub 
      2023 Aug 15.